Insomnia, Brexit and the UPC: a fictional scenario
In our latest article looking at a UPC scenario, Nicola Dagg, Marc Döring, Alex Woolgar, David Por, Philipp Cepl and Laura Thompson consider a case that raises questions about jurisdiction, discovery and Brexit
In this fictional scenario our client is US-based innovative
pharmaceutical company, Jones Pharma Inc. Jones manufactures
and markets worldwide a medical device for the treatment of
insomnia and related sleep disorders, branded SeroNight.
SeroNight is a transdermal patch containing a...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.